News for Eupraxia Pharmaceuticals Inc. (EPRX.TO)

PR NewswireVICTORIA, BC, March 20, 2025 VICTORIA, BC, March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPR

PR NewswireVICTORIA, BC, Feb. 25, 2025 Histological scores and symptom scores continue to improve as EP-104GI dose, and area of esophageal coverage, increa

PR NewswireVICTORIA, BC, Feb. 18, 2025 - Bruce Cousins is retiring, and former CFO Alex Rothwell will assume the roleVICTORIA, BC, Feb. 18, 2025 /PRNewswi

PR NewswireVICTORIA, BC, Nov. 20, 2024 DiffuSphereâ„¢ is designed to enable precise drug delivery at therapeutic dose levels directly into target tissues,

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

Corcept Therapeutics (CORT), a pharmaceutical company specializing in hormone regulation therapies, experienced a significant stock movement with a 5.04% drop i

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024

Eupraxia Pharmaceuticals reports to SEC on latest developments

Eupraxia Pharmaceuticals files report with SEC

New York-based Treasure Global Inc. (TGL) is up over 189 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Eupraxia Pharmaceuticals files regulatory update with SEC

VICTORIA, BC, June 5, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. , a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for...

Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares rose sharply during today’s pre-market trading after the company presented new data from CLEAR outcomes at ACC.24 highlighting value of NEXLETOL® tablets in diverse populations.